As the past two years have shown, the biopharmaceutical industry is more important than ever in producing drugs that improve and save lives. For U.S. biopharmaceutical companies, China continues to be an important market. Securing and enforcing intellectual property (IP) rights in China is critical for U.S. companies to succeed in this growing market and to recoup the tremendous investments in development of new medicines.
The 90-minute program featured presentations by senior United States Patent and Trademark Office (USPTO) IP attorneys and seasoned practitioners with extensive China IP experience.
Topics covered included:
- Challenges and opportunities for U.S. companies as licensors and licensees of biopharmaceutical technologies in China
- An overview of recent changes to IP legislation and patent examination guidelines in China
- China’s newly implemented patent linkage system
- Strategic considerations for licensing of biopharmaceutical patents in China
- Biopharmaceutical patent litigation in China
During the program, participants submitted their questions to a dedicated email box. There was time allotted to respond to participants' questions.
A video recording of this event is now available
Agenda
(All times ET)
Additional information
For more information, visit the registration page or contact Nadine Herbert in the USPTO's Office of Policy and International Affairs (OPIA).
To request an accommodation to participate in this event, please contact Nadine Herbert.
This program is presented by the USPTO’s Global Intellectual Property Academy, a unit of OPIA. OPIA advises the administration and other federal government departments and agencies on domestic and international IP legal and policy issues. It also provides technical assistance and training on IP-related matters to U.S. stakeholders and both U.S. and foreign government officials.
